No Data
Shanghai Rightongene Biotechnology Co., Ltd. (SHSE:688217) Not Doing Enough For Some Investors As Its Shares Slump 28%
The actual controllers of Ruian Gene (688217.SH), Xiong Hui and Xiong Jun, have been placed under residential surveillance measures in designated places for allegedly engaging in illegal operations.
Genetron Holdings Limited (688217.SH) announced that the actual controller and Chairman and CEO respectively of the company have received...
Ruiang Gene (688217.SH): BCR-ABL P210 Fusion Gene Detection Kit has obtained the registration certificate for medical instruments.
On June 5th, Gelonhui reported that Ruiang Genetics (688217.SH) announced that its wholly-owned subsidiary, Suzhou Yuntai Biomedical Technology Co., Ltd.'s BCR-ABL P210 fusion gene detection kit (fluorescent RT-PCR method) has recently obtained the Medical Device Registration Certificate (In Vitro Diagnostic Reagents) issued by the National Medical Products Administration. The approval of the BCR-ABL P210 fusion gene detection kit (fluorescent RT-PCR method) medical device registration certificate is another important breakthrough for Ruiang Genetics in the field of leukemia testing.
Ruiong Gene (688217.SH): Shareholder Zhejiang Health plans to reduce its shareholding by no more than 2%.
On June 4th, Gelunhui reported that Ruiong Gene (688217.SH) announced that due to its shareholder's own capital needs, Zhejiang Dajiankang intends to reduce its total holdings of the company's shares through centralized bidding and bulk transactions by no more than 1,117,116 shares, accounting for no more than 2% of the total share capital of the company. Zhejiang Dajiankang intends to reduce the number of company shares it holds through centralized bidding by no more than 558,558 shares, accounting for no more than 1% of the total share capital of the company, and the total number of shares to be sold within any consecutive 90 calendar days shall not exceed 1% of the company's total number of shares; intends to carry out bulk transactions.
Genetron Holdings Limited (688217.SH): has cumulatively repurchased 1.20% of the company's shares.
As of May 31, 2024, Retechgene (688217.SH) announced that it has cumulatively repurchased 669,621 shares of the company through the Shanghai Stock Exchange trading system using centralized bidding trading, accounting for 1.20% of the total share capital of 55,855,896 shares. The highest and lowest prices for repurchase transactions were 27.67 yuan/share and 22.37 yuan/share respectively. The total amount paid was RMB 17,021,747.99 (excluding transaction fees such as stamp duty and brokerage commission).
About 18.351,400 restricted shares of Rayon Gene (688217.SH) will be listed and distributed from May 17
Rayon Gene (688217.SH) issued an announcement. The restricted shares in circulation in this listing are restricted in the company's initial public offering...
No Data
